Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma

Joe Okumoto1, Shinjiro Sakamoto1, Takeshi Masuda1, Kakuhiro Yamaguchi1, Yasushi Horimasu1, Shintaro Miyamoto1, Taku Nakashima1, Hiroshi Iwamoto1, Noriyasu Fukushima2, Kazunori Fujitaka1, Hironobu Hamada1 and Noboru Hattori1

Abstract:
Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results on admission, we focused on the clinical course of anemia and hemolysis progression after alectinib administration. The patient’s anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.

Key words: alectinib, drug-induced immune hemolytic anemia, lung cancer, anaplastic lymphoma kinase, coombs-negative autoimmune hemolytic anemia

Introduction
The incidence of drug-induced immune hemolytic anemia (DIIHA) is approximately 1 per million yearly (1). Despite its rare occurrence, there are reports of DIIHA caused by frequently used drugs. Thus, the possibility of DIIHA should be considered in connection with their use.

Recently, several drugs against various molecular targets have been developed, resulting in a remarkable improvement in the prognosis of lung cancer harboring a driver mutation. An epidermal growth factor receptor (EGFR) gene mutation and the anaplastic lymphoma kinase (ALK) fusion gene are representative driver mutations in lung cancer and targets of molecular-targeted drugs (2).

ALK-positive lung cancer accounts for approximately 4% of all lung cancer cases (2). ALK domain-targeted tyrosine kinase inhibitors (ALK-TKIs) are being rapidly developed (3). Crizotinib is a first-generation ALK-TKI, whereas alectinib and ceritinib are second-generation and lorlatinib is a third-generation drug. Guidelines recommend alectinib as the primary therapy for ALK-positive lung cancer, making it a key drug for the treatment of this condition.

Anemia accounts for 5-15% of the adverse events associated with alectinib (4). However, to our knowledge, alectinib-induced immune hemolytic anemia (IHA) has not been reported before. We herein report the first case of alectinib-induced IHA in a patient with lung adenocarcinoma. Furthermore, in this case, the direct Coombs’ test [also called the direct antiglobulin test (DAT)] was negative. We therefore also discuss the characteristic findings of patients with DAT-negative autoimmune hemolytic anemia (AIHA).

Case Report
An 85-year-old woman primarily presenting with dyspnea on exertion visited a local hospital in December 2016. Chest X-ray showed left pleural effusion, and she subsequently visited our hospital for a detailed examination. Chest com-
ings showed progressive anemia (7.3 g/dL) and increased
levels of total bilirubin (T-Bil, 2.6 mg/dL), reticulocytes (3.64%), and lactate dehydrogenase (LDH, 281 U/L), whereas a low level of haptoglobin (<10 mg/dL) was reported (Table 1). The patient had macrocytic anemia but no history of stomach surgery, and her serum vitamin B12 and folic acid levels were normal. Furthermore, microspherocytes appeared on a peripheral blood smear (Fig. 1). In addition, the results for the direct Coombs’ test (also called the DAT) were negative. We therefore conducted a CT examination to investigate the cause of hemolytic anemia.

Cheste CT on admission showed no marked change in the primary tumor in the left S7 compared with chest CT performed six months earlier (Fig. 2). Conversely, abdominal CT on admission showed spleen enlargement compared with abdominal CT performed two years earlier. We therefore focused on the clinical course of anemia and hemolysis progression.

Because anemia and hemolysis progression were observed after the administration of alectinib (Fig. 3), we suspected alectinib-induced IHA. Consequently, we instructed the patient to discontinue alectinib and monitored the anemia over time. She needed a blood transfusion only once on hospital admission day 8 for dyspnea on exertion, but there was no further progression of anemia after the discontinuation of alectinib. Subsequently, the anemia and hemolysis gradually improved (Fig. 4). Therefore, she was confirmed to have had DAT-negative alectinib-induced IHA. In addition, the lung cancer has not worsened to date.

**Discussion**

We herein report the first case of alectinib-induced IHA.

---

Table 1. Laboratory Data.

| <Hematology> | <Biochemistry> |
|--------------|----------------|
| WBC 5.710 ×10^6/μL | T-Bil 2.6 mg/dL |
| RBC 2.12 ×10^12/μL | D-Bil 0.8 mg/dL |
| Hb 7.3 g/dL | AST 35 U/L |
| Hct 23.6% | Fe 85 μg/dL |
| MCV 111.3 fL | UIBC 193 μg/dL |
| MCH 34.4 pg | ferritin 17.7 ng/mL |
| MCHC 30.9% | γ-GTP 45 U/L |
| Plt 253 ×10^3/μL | Viat-B12 1.757 pg/mL |
| Specific gravity 1.015 | Na 139 mEq/L |
| Proteinuria (-) | CRP 0.1 mg/dL |
| Hematuria (-) | <Tumor marker> |
| Glucosuria (-) | <Direct Coombs Test> |

WBC: white blood cells, RBC: red blood cells, Hb: hemoglobin, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, Plt: platelets, Ret: reticulocyte, T-Bil: total bilirubin, D-Bil: direct bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, BUN: blood urea nitrogen, Cr: creatinine, Na: sodium, K: potassium, Cl: chloride, TP: total protein, Alb: albumin, Fe: serum iron, UIBC: unsaturated iron binding capacity, CRP: C-reactive protein, CEA: carcinoembryonic antigen.
in a patient with lung adenocarcinoma. It has been reported that penicillin, acetaminophen, and alpha-methyl dopamine are frequent causes of DIIHA, but many other drugs can also be involved (5). DIIHA is classified according to three mechanisms of action: drug-absorption (hapten-induced), immune complex, or autoantibody (Table 2) (5). In this patient, prolonged drug administration, gradual progressive anemia, and extravascular hemolysis corresponded to the clinical features of the autoantibody type. In addition, the progression of splenomegaly after the administration of alectinib suggested extravascular hemolysis. Recently, immune checkpoint inhibitor (ICI)-induced IHA has been described in numerous case reports (6). The mechanism underlying ICI-induced IHA is considered to relate to the imbalance of regulatory T cells and the overactivity of B and T cells (7, 8). While this mechanism is assumed to be autoantibody type, it is still incompletely understood. In contrast, only case reports of hemolytic anemia with molecular-targeted agents, such as EGFR-TKIs and ALK-TKIs, have been published (9). TKIs are presumed to interfere with B-cell activation and the in-
duction of the humoral immune response through their off-target multikinase inhibitory effects (10), which may explain why these molecular-targeted agents carry a lower risk of DIIHA than cytotoxic anti-cancer agents and ICIs. In the present patient, first-line pemetrexed therapy may have contributed to the onset of alectinib-induced IHA. Cases of rheumatoid arthritis induced by pemetrexed therapy have been reported (11), and recent investigations have demonstrated that pemetrexed promotes lymphocyte activation (12). For this reason, first-line pemetrexed therapy probably induced autoantibody production and caused alectinib-induced IHA despite pemetrexed discontinuation. However, the characteristics of the molecular-targeted agents may have suppressed excessive autoantibody production and resulted in DAT-negative DIIHA rather than DAT-negative DIIHA. Nevertheless, few reports have been published on DAT-negative DIIHA. Thus, in the following paragraph, we discuss DAT-negative AIHA instead of DAT-negative DIIHA.

DAT-negative AIHA, which accounts for approximately 10% of all AIHA cases (15), is principally attributable to (a) RBC-bound IgG below the threshold of detection using standard methods (>90% of cases (16)); (b) a low affinity of IgG; and (c) RBC-bound IgA or IgM (17). When AIHA patients are DAT negative, evaluating RBC-bound IgG using an immunoradiometric method is recommended (17). In the present case, we were unable to evaluate RBC-bound IgG due to no sample being available. The degree of anemia and hemolysis is reported to be significantly milder in DAT-negative AIHA than in DAT-positive AIHA (18). In the present patient, mild anemia, chronic clinical course, and immediate improvement of anemia after the discontinuation of
Alectinib corresponded to the clinical features of DAT-negative AIHA. Based on these clinical and laboratory findings, the patient was diagnosed with alectinib-induced IHA.

In summary, we encountered a case of alectinib-induced IHA in a patient who presented with gradually progressing anemia. To our knowledge, alectinib-induced IHA has not been reported before; in addition, in this report, we present the first case in a patient with lung adenocarcinoma.

In conclusion, we should focus on the clinical course of anemia and hemolysis progression before and after administration of the offending drug in patients with suspected DI-IHA. This is especially applicable in DAT-negative cases where clinical suspicion is high.

The authors state that they have no Conflict of Interest (COI).

References

1. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 24: 143-150, 2010.
2. Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 102: 122-134, 2016.
3. Thai AA, Solomon BJ. Treatment of ALK-positive non-small cell lung cancer: recent advances. Curr Opin Oncol 30: 84-91, 2018.
4. Open-label randomized PhaseIII Study of the Efficacy and Safety of CH5424802(AF802) in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer with Crizotinib control [Internet]. [cited 2019 Nov 19]. Available from: http://image.packageinsert.jp/pdf.php?mode=1&yjcode=4291032M1029
5. Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician 69: 2599-2606, 2004.
6. Khan U, Ali F, Khurram MS, Zaka A, Hadid T. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 5: 15, 2017.
7. Michel M. Warm autoimmune hemolytic anemia: advances in pathophysiology and treatment. Presse Med 43: e97-e104, 2014.
8. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev 24: 195-210, 2010.
9. Sakhri L, Mennecier B, Quoix A. Hemolytic anemia erlotinib treatment. Rev Pneumol Clin 69: 345-350, 2013.
10. De Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 122: 227-238, 2013.
11. Anazawa R, Taniyama D, Kamata H, Miyamoto K, Sakamaki F. Two cases of rheumatoid arthritis after anticancer chemotherapy with pemetrexed for non-small-cell lung cancer. Ann Jpn Respir Soc 2: 269-273, 2013 (in Japanese, Abstract in English).
12. Schae D, Geeganage S, Amaladas N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin Cancer Res 25: 7175-7188, 2019.
13. Takahashi T. Direct Antiglobulin test-negative autoimmune hemolytic anemia. Acta Haematol 140: 18-19, 2018.
14. Kamesaki T. Diagnosis and treatment of hemolytic anemia. Rinsho Ketsueki (Jpn J Clin Hematol) 56: 1894-1902, 2015.
15. Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol 42: 156-164, 2005.
16. Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol 84: 98-101, 2009.
17. Parker V, Tormey CA. The direct antiglobulin test: indications, interpretation, and pitfalls. Arch Pathol Lab Med 141: 305-310, 2017.
18. Kamesaki T. Autoimmune hemolytic anemia. Nihon Naika Gakkai Zasshi (J Jpn Soc Intern Med) 103: 1599-1608, 2014 (in Japanese).

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).